UBS Group Cuts Danaher (NYSE:DHR) Price Target to $250.00

Danaher (NYSE:DHR) had its target price trimmed by UBS Group from $270.00 to $250.00 in a research report released on Wednesday morning,Benzinga reports. The firm currently has a buy rating on the conglomerate’s stock.

Several other equities analysts have also commented on the stock. Wells Fargo & Company decreased their price objective on shares of Danaher from $240.00 to $212.00 and set an “equal weight” rating on the stock in a report on Wednesday. Argus set a $265.00 target price on shares of Danaher in a report on Wednesday, January 14th. KeyCorp reiterated an “overweight” rating on shares of Danaher in a report on Thursday, January 29th. Robert W. Baird reduced their target price on shares of Danaher from $251.00 to $249.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Finally, Leerink Partners increased their target price on shares of Danaher from $260.00 to $270.00 and gave the stock an “outperform” rating in a report on Friday, January 16th. Seventeen analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $242.45.

Danaher Stock Performance

Shares of DHR stock opened at $177.31 on Wednesday. The firm’s 50 day moving average price is $195.75 and its 200-day moving average price is $213.86. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.51 and a current ratio of 1.87. Danaher has a one year low of $175.00 and a one year high of $242.80. The firm has a market cap of $125.49 billion, a P/E ratio of 34.30, a P/E/G ratio of 2.42 and a beta of 0.95.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, April 21st. The conglomerate reported $2.06 EPS for the quarter, topping the consensus estimate of $1.94 by $0.12. Danaher had a net margin of 14.89% and a return on equity of 10.91%. The firm had revenue of $5.95 billion for the quarter, compared to analyst estimates of $6 billion. During the same period in the prior year, the business posted $1.88 EPS. The business’s revenue for the quarter was up 3.7% compared to the same quarter last year. Danaher has set its FY 2026 guidance at 8.350-8.550 EPS. As a group, equities research analysts predict that Danaher will post 8.43 EPS for the current year.

Danaher Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, April 24th. Shareholders of record on Friday, March 27th were issued a dividend of $0.40 per share. This is a boost from Danaher’s previous quarterly dividend of $0.32. The ex-dividend date was Friday, March 27th. This represents a $1.60 dividend on an annualized basis and a yield of 0.9%. Danaher’s dividend payout ratio (DPR) is currently 30.95%.

Insider Transactions at Danaher

In other Danaher news, EVP Gregory M. Milosevich sold 1,320 shares of the stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $208.01, for a total transaction of $274,573.20. Following the sale, the executive vice president directly owned 5,099 shares in the company, valued at $1,060,642.99. This represents a 20.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 10.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Danaher

A number of large investors have recently modified their holdings of DHR. JPL Wealth Management LLC purchased a new stake in shares of Danaher in the 3rd quarter valued at approximately $25,000. Elevated Capital Advisors LLC purchased a new stake in shares of Danaher in the 4th quarter valued at approximately $26,000. WFA of San Diego LLC purchased a new stake in shares of Danaher in the 2nd quarter valued at approximately $26,000. ANTIPODES PARTNERS Ltd purchased a new stake in shares of Danaher in the 3rd quarter valued at approximately $27,000. Finally, Hilton Head Capital Partners LLC purchased a new stake in shares of Danaher in the 4th quarter valued at approximately $27,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Key Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Guggenheim reiterated a Buy rating on Danaher, supporting demand-side interest from institutional buyers. Guggenheim Reaffirms Buy
• Positive Sentiment: An analyst price-target lift to $232 signals buy-side upside vs. current levels, which can support the stock if investors focus on medium-term earnings guidance. Price Target Raised to $232
• Neutral Sentiment: Danaher priced ~€3.0 billion of euro-denominated senior notes across maturities (2028–2038). This raises liquidity for operations or M&A but increases long-term debt on the balance sheet. Senior Notes Offering
• Neutral Sentiment: Coverage pieces question whether the recent share weakness makes DHR an attractive value play — useful for long-term investors but not an immediate catalyst. Valuation Article
• Negative Sentiment: Danaher agreed to settle shareholder litigation tied to its post‑pandemic outlook for about $172.5M, a direct hit to cash and a reminder of past forecasting issues; that likely pressured sentiment. Settlement Report
• Negative Sentiment: Short interest rose ~17.8% to 8.18M shares as of April 15 (≈1.3% of float; short-interest ratio ~2.5 days), indicating increased speculative/hedged bearish positioning that can amplify downward moves.
• Negative Sentiment: Morgan Stanley trimmed its price target (from $270 to $255), and UBS issued a pessimistic forecast—both moves add analyst-driven downside pressure despite differing target levels. Morgan Stanley PT Cut UBS Forecast
• Negative Sentiment: Analysts/commentary flag Danaher’s Masimo acquisition as adding long-term potential but creating near-term margin and integration pressure, a nearer-term risk to earnings momentum. Masimo Deal Commentary

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.